The present invention relates to bioengineered collagen constructs and methods for the preparation and use of said constructs. The constructs and methods may find application in, but are not limited to, the provision of replacement tissue and/or cells, and/or the delivery of agents to biological targets such as tissues and cells. The constructs and methods may also find application in, but are not limited to, replacing endothelial tissue.

The invention relates to immuno-modulatory progenitor (IMP) cells and their use in therapy.

Methods of preparing platelet-rich plasma (PRP) compositions are disclosed which include adding CD34+ cells to the PRP composition. In addition, the concentration of stromal-derived factor-1 (SDF-1) in the PRP composition may be adjusted to a pre-determined value. The compositions may have elevated levels of white blood cells but reduced levels of neutrophils. Compositions produced by the method are also disclosed.

The present invention concerns a method of producing brown/beige adipocytes from white adipose tissue cells and/or mesenchymal stem cells, in particular from subcutaneous white adipose tissue cells, and the use of said brown/beige adipocytes in a cell based therapy of a subject or in screening platforms.

A method of culturing autogenous cells as well as a method of treating a mammalian patient is described. The cells are cultured on a substrate material having a surface treated with a fatty acid ester so as to have a strong hydrophobic surface and autogenous plasma obtained from a blood sample of the patient is used as a growth medium in order to culture the cells. The substrate material is also used as a transfer dressing for transferring the cultured cells to the patient and as a wound cover dressing. The invention also describes a kit as well as a system for culturing autogenous cells using the culture method.

The invention relates to immuno-oncology mesodermal progenitor (ioMP) cells and their use in therapy.

The present invention concerns a method of producing brown/beige adipocytes from white adipose tissue cells and/or mesenchymal stem cells, in particular from subcutaneous white adipose tissue cells, and the use of said brown/beige adipocytes in a cell based therapy of a subject or in screening platforms.

Various systems and methods of producing animal derived products, such as for cultivated meat, are described herein. For example, one embodiment includes the steps of obtaining components of a cell-culture medium by sustainably harvesting blood components from living animals to produce a cell-culture medium suitable for in vitro cell culture and culturing cells in the cell-culture medium to produce a cultivated meat product. In some embodiments, the disclosure generally relates to sustainably harvesting blood components for the cultivation of meat and other animal derived products, e.g., by repeatedly extracting blood components in a manner which does not kill a non-human animal. In some embodiments, the non-human animals can be farmed for the purpose of sustainably extracting whole blood and/or blood products. In some embodiments, the harvested blood product may be used to produce a cultivated meat product or other animal derived product, such as a muscle tissue, a fat tissue or heme.

Disclosed are compositions of matter, cells, protocols and procedures useful for augmentation of one or more therapeutic activities of fibroblast cellular populations. In one embodiment fibroblasts are pretreated with growth factor-comprising composition(s), wherein the growth factor(s) may be cytokines, peptides, and/or proteins. In another embodiment fibroblasts are cultured with platelet rich plasma and/or derivatives from platelet rich plasma. In another embodiment, fibroblasts are cultured under hypoxic conditions prior to administration to an individual. The disclosure further provides means of assessment of fibroblast activity in vitro, including wound repair assay and cytokine production, for example.

A particulate lyophilized platelet lysate composition suitable for use as a cell culture medium can include growth factors, cytokines, and chemokines released from lysis of source platelets, wherein cellular debris from the source platelets is removed (partially or fully) by filtration. The growth factors, cytokines, and chemokines are lyophilized to form a particulate lyophilized platelet lysate composition.